Elsevier

Pediatric Neurology

Volume 51, Issue 5, November 2014, Pages 657-662
Pediatric Neurology

Original Article
Erythropoietin and Hypothermia for Hypoxic-Ischemic Encephalopathy

https://doi.org/10.1016/j.pediatrneurol.2014.08.010Get rights and content

Abstract

Background

Erythropoietin is neuroprotective in animal models of neonatal hypoxic-ischemic encephalopathy. We previously reported a phase I safety and pharmacokinetic study of erythropoietin in neonates. This article presents the neurodevelopmental follow-up of infants who were enrolled in the phase I clinical trial.

Methods

We enrolled 24 newborns with hypoxic-ischemic encephalopathy in a dose-escalation study. Patients received up to six doses of erythropoietin in addition to hypothermia. All infants underwent neonatal brain magnetic resonance imaging (MRI) reviewed by a single neuroradiologist. Moderate-to-severe neurodevelopmental disability was defined as cerebral palsy with Gross Motor Function Classification System levels III-V or cognitive impairment based on Bayley Scales of Infant Development II mental developmental index or Bayley III cognitive composite score.

Results

Outcomes were available for 22 of 24 infants, at mean age 22 months (range, 8-34 months). There were no deaths. Eight (36%) had moderate-to-severe brain injury on neonatal MRI. Moderate-to-severe disability occurred in one child (4.5%), in the setting of moderate-to-severe basal ganglia and/or thalamic injury. Seven infants with moderate-to-severe watershed injury exhibited the following outcomes: normal (three), mild language delay (two), mild hemiplegic cerebral palsy (one), and epilepsy (one). All 11 patients with a normal brain MRI had a normal outcome.

Conclusions

This study is the first to describe neurodevelopmental outcomes in infants who received high doses of erythropoietin and hypothermia during the neonatal period. The findings suggest that future studies are warranted to assess the efficacy of this new potential neuroprotective therapy.

Introduction

Perinatal hypoxic-ischemic encephalopathy (HIE) is an important cause of neonatal encephalopathy and occurs in one to three per 1000 term births,1, 2 affecting up to 12,000 infants each year in the United States. Therapies remain limited. Hypothermia initiated within 6 hours of birth provides modest improvements in outcome.3, 4, 5, 6, 7 Yet despite this therapy, over 40% of infants with moderate-to-severe HIE die or suffer moderate-to-severe disabilities including cerebral palsy, intellectual impairment, and epilepsy. New neuroprotective therapies are needed to further reduce the unacceptably high risk of adverse outcomes after HIE.

The hematopoietic cytokine erythropoietin (Epo) has neuroprotective and neuroregenerative effects in the brain.8, 9, 10, 11, 12, 13 High doses of Epo administered to neonatal rodents after hypoxic-ischemic brain injury result in improved histologic and functional outcomes and enhanced neurogenesis and repair.14, 15, 16, 17, 18, 19, 20 In a nonhuman primate model of HIE in which hypothermia alone did not significantly improve outcomes, the combined treatment of Epo and hypothermia resulted in a significantly lower rate of death or moderate-to-severe cerebral palsy than did treatment with saline alone (0% versus 43%, P < 0.05).21 Compared with animals treated with saline, those that received both Epo and hypothermia also demonstrated improved long-term motor and cognitive responses, enhanced cerebellar growth, and improved fractional anisotropy on early diffusion tensor imaging.21

Two clinical trials reported that human infants with HIE who received five to seven doses of Epo during the first week of age, in the absence of hypothermia, experienced improved neurological outcomes.22, 23 After hypothermia became the standard of care in the treatment of HIE, we evaluated the safety and pharmacokinetics of combined Epo and hypothermia therapy in a phase I trial and found that multiple doses of Epo ranging from 250 to 2500 U/kg IV appeared safe in the neonatal period.24 However, longer term outcome data have yet to be reported in cooled infants who received high-dose Epo as a neonate. Therefore, we present the neurodevelopmental outcomes of infants with HIE who received high doses of Epo and hypothermia therapy during the first week of age.

We previously reported a phase I safety and pharmacokinetic study of Epo in neonates.24 The current article presents the neurodevelopmental follow-up of infants who were enrolled in the phase I clinical trial. In an open-label dose-escalation study,24 24 newborns ≥37 weeks of gestational age undergoing hypothermia for HIE received one of the following four Epo doses IV: 250 (n = 3), 500 (n = 6), 1000 (n = 7), and 2500 U/kg per dose (n = 8). We studied these doses to determine which would achieve target plasma Epo levels based on available data from animal studies. We administered up to six doses of Epo every 48 hours, starting by 24 hours of age. Each patient met inclusion and exclusion criteria for encephalopathy and perinatal depression as previously described.24, 25 All patients also underwent standard 72 hours of hypothermia therapy using either whole body (n = 21) or head (n = 3) cooling. All patients received a brain magnetic resonance imaging (MRI) at the completion of hypothermia therapy as part of routine clinical care. A study neuroradiologist (A.J.B.) who was blinded to patient outcomes interpreted the MRI studies using a previously validated scoring system.26 The MRI was classified as normal, abnormal with a predominant watershed pattern of injury, or abnormal with predominant basal ganglia and/or thalamic injury. Severity of injury was dichotomized as being either moderate and/or severe or mild and/or normal as previously described.27 The study received institutional review board's approval at each of five participating hospitals.

After hospital discharge, patients were evaluated in the high-risk infant follow-up programs of each of the five study sites, as part of routine clinical care. During these visits, patients were evaluated for neurodevelopmental abnormalities: cerebral palsy, tone abnormalities, motor delay, language delay, and presence of seizures. The Bayley Scales of Infant Development (Bayley) II or III was performed in 16 patients at median age 24.4 months (range, 13-34 months). The eight patients who did not receive Bayley testing were either enrolled at a site where Bayley testing is not performed routinely (n = 5) or did not receive Bayley testing as part of their follow-up assessment (n = 3). We defined moderate-to-severe disability as either a clinical diagnosis of cerebral palsy with Gross Motor Function Classification System (GMFCS) III-V or moderate-to-severe cognitive delay based on Bayley II MDI of <70 or Bayley III cognitive composite score of <80. Mild impairment was defined as cognitive or language delays requiring referral to early intervention services, epilepsy, or abnormal neurological examination without a diagnosis of cerebral palsy or functional impairment.

Section snippets

Results

Twenty-four of 26 infants consented to the study. Hypotonia, lethargy, and poor suck were the most common signs of encephalopathy (Table 1). Fifteen infants (63%) had a 10-minute Apgar score of ≤5, and mean arterial or venous cord pH was 6.87 (S.D. = 0.14). Almost half of infants (45.8%) were delivered via emergent cesarean section. A sentinel event occurred in seven patients (29%), including placental abruption (four), uterine rupture (two), and prolapsed cord (one). Over half (n = 13) had

Discussion

In this small, open-label, phase I trial of combined Epo and hypothermia therapy for HIE, we report no deaths and a relatively low rate (4.5%) of moderate-to-severe neurodevelopmental disability at median age 22 months. This study lacked controls and was not designed to test efficacy. However, our data provide evidence extending beyond the neonatal period that high-dose Epo given in conjunction with hypothermia does not worsen outcomes when given to newborns with HIE.

This study is subject to a

Conclusions

High-dose Epo does not appear to worsen neurodevelopmental outcomes when administered in conjunction with therapeutic hypothermia for HIE. In addition to the neonatal safety data we previously reported, the neurodevelopmental outcome data presented here provide additional reassurance that this new potential therapy has no adverse long-term consequences and therefore appears safe. We eagerly await the results of future trials that will provide additional data regarding whether this promising

References (46)

  • S. Shankaran et al.

    Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy

    N Engl J Med

    (2005)
  • S.E. Jacobs et al.

    Whole-body hypothermia for term and near-term newborns with hypoxic-ischemic encephalopathy: a randomized controlled trial

    Arch Pediatr Adolesc Med

    (2011)
  • G. Simbruner et al.

    Systemic hypothermia after neonatal encephalopathy: outcomes of neo.nEURO.network RCT

    Pediatrics

    (2010)
  • D.V. Azzopardi et al.

    Moderate hypothermia to treat perinatal asphyxial encephalopathy

    N Engl J Med

    (2009)
  • S. Juul

    Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage

    Acta Paediatr Suppl

    (2002)
  • S.E. Juul et al.

    Recombinant erythropoietin is neuroprotective in a novel mouse oxidative injury model

    Dev Neurosci

    (2008)
  • E.J. Demers et al.

    Erythropoietin protects dopaminergic neurons and improves neurobehavioral outcomes in juvenile rats after neonatal hypoxia-ischemia

    Pediatr Res

    (2005)
  • C. Dame et al.

    The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential

    Biol Neonate

    (2001)
  • R. Reitmeir et al.

    Post-acute delivery of erythropoietin induces stroke recovery by promoting perilesional tissue remodelling and contralesional pyramidal tract plasticity

    Brain

    (2011)
  • M. Iwai et al.

    Erythropoietin promotes neuronal replacement through revascularization and neurogenesis after neonatal hypoxia/ischemia in rats

    Stroke

    (2007)
  • B.A. Kellert et al.

    A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats

    Pediatr Res

    (2007)
  • Y.S. Chang et al.

    Erythropoietin improves functional and histological outcome in neonatal stroke

    Pediatr Res

    (2005)
  • F.F. Gonzalez et al.

    Erythropoietin sustains cognitive function and brain volume after neonatal stroke

    Dev Neurosci

    (2009)
  • Cited by (0)

    Clinical Trial Registration: This trial is registered at www.clinicaltrials.gov (NCT00719407).

    View full text